The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Amylin analogs for the treatment of obesity without diabetes: present and future
Abstract
Introduction Obesity is a pandemic, linked with increased morbidity including diabetes mellitus (DM) and certain cancer types. Amylin is a major regulatory hormone for satiation and food intake perception in humans. Amylin analogs (pramlintide and cagrilintide) are emerging as promising anti-obesity agents in non-DM subjects. Areas covered Pramlintide, the first amylin analog, initially used for the treatment of both type 1 and type 2 DM, has demonstrated weight-lowering action. Clinical trials confirmed a weight loss exceeding 3% in the study period without major untoward effects, which was maintained beyond the follow-up period. Recently, cagrilintide, a long-lasting synthetic amylin analog has been introduced. Cagrilintide has achieved adequate weight loss, reaching even more than 10% of the total weight in early clinical trials. However, adverse gastrointestinal effects, particularly nausea, were more frequent compared with pramlintide. Clinical trials have also confirmed the effectiveness of cagrilintide in comparison with glucagon-like peptide 1 receptor agonists. Expert opinion Amylin analogs will certainly enrich the growing therapeutic armamentarium aimed at tackling obesity. The most exciting future research venue could be the development of their combinations with other weight-lowering drugs, especially dual and triple incretin-based co-agonists, thus potentially providing massive weight-loss effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The body composition effects of the amylin analogs in humans are unknown but there is animal evidence that they spare lean mass. [41]”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [41]
Citations
Cites
Boutari, C., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155217 · Cited by 1,068
Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1732-4 · Cited by 205
Aronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2003 · Cited by 178 · cited 10×
“In all studies, nausea emerged as the major adverse effect [31– 35].”
InfluentialSmith, S. R., Aronne, L. J., Burns, C. M., Kesty, N. C., Halseth, A. E., & Weyer, C. (2008) · Diabetes Care · doi:10.2337/dc08-0029 · Cited by 172 · cited 10×
“Specific time-related data on the effect of pramlintide on weight were used to ascertain the dose-dependent efficacy: weight loss under 120 μg vs. 360 μg was 3.2 kg vs. 3.3 kg in the 4 th month and 6.1 kg vs. 7.2 kg in the 12 th month, respectively [32].”
InfluentialDevelopment of Cagrilintide, a Long-Acting Amylin Analogue
Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., Dornonville de la Cour, C., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00565 · Cited by 129
Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts
Alam, A., Moonga, B., Bevis, P., Huang, C., & Zaidi, M. (1993) · Experimental Physiology · doi:10.1113/expphysiol.1993.sp003679 · Cited by 99
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73
Amylin as a Future Obesity Treatment
Dehestani, B., Stratford, N. R., & Roux, C. W. L. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21071 · Cited by 72 · cited 4×
“Cagrilintide is a long-acting molecule with a significant affinity for the calcitonin G protein-coupled receptor [7,10,27].”
InfluentialMelson, E., Miras, A. D., & Papamargaritis, D. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0144 · Cited by 46 · cited 1×
“Cagrilintide acts as a long-acting amylin analog and has been already used in two Phase 2 studies, either alone or as a combination treatment with semaglutide [39,44].”
Research works printed but not linked: 35
- 10.1016/j.metabol.2018.09.005 · DOI
- 10.1592/phco.26.11.1626 · DOI
- 10.1097/CRD.0000000000000513 · DOI · Paper page
- 10.1124/pr.115.010629 · DOI · Paper page
- 10.1073/pnas.84.23.8628 · DOI · Paper page
- 10.1152/physrev.00042.2009 · DOI · Paper page
- 10.1016/j.molmet.2017.11.009 · DOI · Paper page
- 10.1016/j.physbeh.2014.01.013 · DOI
- 10.1016/j.physbeh.2010.03.001 · DOI
- 10.1016/j.biopsych.2016.12.028 · DOI
- 10.1038/npp.2013.66 · DOI
- 10.1152/ajpendo.00087.2015 · DOI
- 10.1016/j.tem.2010.03.006 · DOI
- 10.1016/j.tem.2016.11.004 · DOI
- 10.1152/ajprenal.1996.270.2.F289 · DOI
- 10.3389/fendo.2023.1104662 · DOI
- 10.2174/1381612023393341 · DOI
- 10.1016/j.clinthera.2007.04.005 · DOI
- 10.1016/j.clinthera.2005.10.009 · DOI
- 10.1016/j.metabol.2003.06.003 · DOI
- 10.1038/oby.2004.76 · DOI
- 10.1097/MED.0000000000000716 · DOI
- 10.1111/j.1463-1326.2011.01465.x · DOI
- 10.1152/ajpendo.00514.2015 · DOI
- 10.1111/j.1463-1326.2010.01337.x · DOI
- 10.1038/oby.2009.184 · DOI
- 10.1038/oby.2009.478 · DOI
- 10.1152/ajpendo.00217.2007 · DOI
- 10.1038/oby.2007.626 · DOI
- 10.1016/S0140-6736(21)01751-7 · DOI · Paper page
- 10.1016/S0140-6736(21)00845-X · DOI · Paper page
- 10.1016/j.biopha.2024.116150 · DOI
- 10.1007/s13300-023-01506-1 · DOI
- 10.1080/14656566.2023.2237414 · DOI
- 10.1002/dmrr.3503 · DOI
Cited by
Sorted by citations
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?
Ryan, D. H. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09967-4 · Cited by 34
Metadata
- Authors
- Panou, T., Gouveri, E., Popovic, D. S., & Papanas, N.
- Affiliations
- Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece
- Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Novi Sad, Serbia
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2024-09-30
- Volume
- 17
- Issue
- 10
- Pages
- 891-899
- ISSN
- 1751-2433
- 1751-2441
- Cited by
- 5
- References
- 9
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amylin analogs for the treatment of obesity without diabetes: present and future. https://app.cochat.ai/papers/10.1080/17512433.2024.2409403
- The paper
- Panou, T., Gouveri, E., Popovic, D. S., & Papanas, N. (2024). Amylin analogs for the treatment of obesity without diabetes: present and future. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2024.2409403
